GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
GAAP EPS in the quarter was also $1.06, up 13.9% from the year-ago level.
Revenue Details
The company reported revenues of $5 billion, up 3% year over year on a reported basis and 2% organically. The top line beat the Zacks Consensus Estimate by 0.1%. Total company orders increased 3% organically year over year.
Revenues were driven by strength in the U.S. market across all segments, especially in the Imaging and Pharmaceutical Diagnostics segments.
Segmental Details
Imaging
Revenues from this segment totaled $2.2 billion, up 2% year over year on a reported basis and 1% organically.
Segment EBIT was $188 million, down 10% year over year.
Advanced Visualization Solutions
Revenues totaled $1.29 billion, up 3% year over year on a reported basis and 2% on an organic basis.
Segment EBIT was $267 million, up 4% year over year.
Patient Care Solutions
Revenues amounted to $778 million, up 1% year over year on a reported basis and flat organically.
Segment EBIT was $60 million, down 23% year over year.
Pharmaceutical Diagnostics
Revenues totaled $729 million, up 14% year over year and 5% on an organic basis.
Segment EBIT was $213 million, up 7% year over year.
Margins
Net income margin was 9.7%, up 80 basis points from the prior-year level, primarily attributable to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the second quarter was $344 million compared with $300 million a year ago.
Financial Position
GEHC exited the second quarter with cash, cash equivalents and investments of $3.76 billion compared with $2.47 billion in the previous quarter.
Total assets increased to $35.5 billion from $33.59 billion on a sequential basis.
2025 Guidance
GE HealthCare raised its earnings and organic revenue guidance for 2025.
The company now expects adjusted EPS in the range of $4.43-$4.63, up from $3.90-$4.10 expected previously. The guide includes approximately 45 cents of unfavorable impact of tariffs. Revenues are now anticipated to grow 3% organically, up from 2-3% expected previously and therefore reflecting continued demand for its products and services. The Zacks Consensus Estimate for 2025 EPS and revenues is pegged at $4.02 and $20.31 billion, respectively.
Zacks Rank and Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX.
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today's Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
DecisionRules.io Deepens US Commitment with Local Team Expansion and Increased Industry Engagement
Following rapid adoption of its AI-powered Business Rules Engine, the Prague-based firm is hiring US-based experts and increasing its presence at key industry events to support its growing North American client base. Wilmington, Delaware--(Newsfile Corp. - August 1, 2025) - a leader in next-generation Business Rules Management Systems (BRMS), today announced a significant expansion of its US operations, including the hiring of local employees and a planned increase in its presence at major American industry events. This move is fueled by the rapid adoption of its AI-driven decision automation platform by US companies seeking to move beyond the limitations of legacy rules engines. To view an enhanced version of this graphic, please visit: As a proven enterprise solution with an established foothold in the North American market, next phase of growth focuses on building a robust, on-the-ground team to provide direct partnership and expert support to its clients. "The response from the US market has been phenomenal. It has confirmed that businesses are not just ready for, but are actively seeking, a more intelligent and agile way to manage their core logic," said Petr Lev, Co-Founder and CTO of "Expanding our local team is the natural next step. Hiring US-based experts is crucial for providing the hands-on, strategic partnership our clients value as they integrate AI into their decision-making processes." This success is underscored by the company's continuous recognition as a High Performer in 2024 and 2025 in the G2 Grid Report for Decision Management Platforms, cementing its position as a rising industry leader. This powerful combination of accessibility and speed is paired with a core focus on explainable AI (XAI). In regulated industries, the ability to understand why a decision was made is paramount. The platform provides a transparent, human-readable audit trail, solving the "black box" problem that has plagued earlier AI systems. "The traction we're seeing proves that companies are tired of trying to fly a modern jet with just a compass and the naked eye," added Lev. "Our platform is the advanced 'glass cockpit' for their business. The reason it's resonating so deeply is that it delivers both the intelligence of modern AI to navigate any conditions and the transparent instrumentation that business requires. Our growing investment in the US is a direct reflection of our commitment to helping even more American companies upgrade their controls."
CBC
2 hours ago
- CBC
Quebec physicians warn of deepfake scams using their likeness to sell medications
Quebec doctors are sounding the alarm over recent deepfake videos that have been appearing online, saying they can erode public trust in the medical system and put people's health at risk. The AI-generated videos use the likeness of real doctors to give questionable health-care advice and falsely advertise or sell certain products. "It is something that is putting a lot of damage on all physicians in Quebec and in Canada," said Dr. François Marquis, chief of intensive care at Maisonneuve-Rosemont Hospital in Montreal. Marquis said he was in disbelief when he first learned his image was being used in a deepfake video. He received phone calls from people saying "you're all over Facebook," he said, "or that you have discovered something and they want to know if it's true and if they can get the drugs." Marquis said the problem is that his face is known and that he's trusted. "So it's not only my patients, it's any patient who's trusting me or any patient trusting physicians at large," he said, explaining how people can be duped. Dr. Alain Vadeboncoeur, an emergency physician at the Montreal Heart Institute, said his image has also been used to falsely promote various products. In the past week alone, he says four different videos were brought to his attention. In the videos, he's seen talking about urologic matters, or other topics related to prostate cancer, sexual dysfunction and penis enlargement, he said, adding those aren't in his area of expertise. "My main concern is about the people. They trust me, I guess, and they follow this advice and they could make their own health in jeopardy because of those," Vadeboncoeur said. Doctors worry of health risks for patients Marquis echoed similar concerns surrounding patients' health and the risks involved. "The first danger is that you don't know what it is that they're taking," Marquis said. While the product may be inert, it could still cause side effects or react when mixed with other medications or remedies, he explained. "The other problem is that some people will actually stop taking their usual medication to take this fake drug," Marquis said, including life-saving medication like insulin or blood thinners, for example. Previously, the most targeted victims of deepfakes were high-profile celebrities, politicians and pro athletes. Using someone who is credible in the community can make it even more difficult to decipher what's real and what's fake. While Vadeboncoeur doesn't like that his image is being used and manipulated, how he feels about it isn't the issue. "The main issue is that people do buy the stuff that's announced there," he said, adding it seems to be all about the money and amounts to fraud. Fenwick McKelvey, an associate professor in information and communication technology policy at Concordia University, said online scams are becoming more personalized because of how simple it is to make AI-generated deepfakes. "It really creates an issue where you can make these types of frauds more effective, cheaper,and it's harder for the everyday citizen to detect," he said. Marquis has felt the repercussions of that personally, after a person who was taken for a few hundred dollars in an online scam showed up at the hospital demanding his money back. "So that's a real problem because it's not just about, you know, me and the deepfake, now it's about the security of the people in the hospital," he said. Doctors not allowed to promote one product over another In Quebec, it is against the law for physicians to personally promote the use of one product over another. "Specifically, saying, 'This medication is better than this one.' We cannot do that," Marquis said. While there is no straightforward answer on how people can protect themselves, being wary of any endorsements selling products on social media is a good place to start. "Very often you can at least see some labelling of online ads. When you see that and it looks like it's from someone you might know or a doctor but it's also an advertisement, that's something to be more skeptical about," McKelvey said.
Globe and Mail
3 hours ago
- Globe and Mail
Hawkins (HWKN) Q1 Revenue Rises 15%
Key Points GAAP revenue reached a record $293.3 million in Q1 FY2026, but missed analyst estimates by 3%. Earnings per share were $1.40 for the first quarter of fiscal 2026, also below the $1.45 GAAP consensus estimate. Water Treatment segment revenue surged 28% year over year (GAAP), driven by acquisitions. These 10 stocks could mint the next wave of millionaires › Hawkins (NASDAQ:HWKN), a specialty chemical and ingredient company focusing on water treatment, health and nutrition, and industrial solutions, announced its first quarter fiscal 2026 financial results on July 30, 2025. The headline news: the company posted record GAAP revenue and gross profit for Q1 FY2026, but fell short of analyst expectations for both revenue and earnings per share (GAAP). Actual GAAP revenue was $293.3 million, below the $302.3 million GAAP consensus, while reported GAAP earnings per share were $1.40 versus the $1.45 estimate. Despite these shortfalls, the company delivered significant top-line growth, with GAAP revenue increasing 15% and highlighted its Water Treatment business as a key driver for the period. Metric Q1 FY26(3 mos. ended Jun 29, 2025) Q1 FY26 Estimate Q1 FY25(3 mos. ended Jun 30, 2024) Y/Y Change EPS (GAAP) $1.40 $1.45 $1.38 1.4% Revenue (GAAP) $293.3 million $302.3 million $255.9 million 14.6 % Adjusted EBITDA $57.6 million $50.9 million 13.2% Gross Profit $72.4 million $64.7 million 11.9% Net Income $29.2 million $28.9 million 1.0 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report. Business Overview and Strategic Focus Hawkins is a U.S. company specializing in the formulation, blending, and distribution of chemicals and ingredients. Its business serves municipal water suppliers, food manufacturers, dietary supplement companies, and industrial clients. The company organizes its operations into three segments: Water Treatment, Food & Health Sciences, and Industrial Solutions. Recently, the company has sharpened its focus on the Water Treatment segment, pursuing acquisitions to scale operations and capture higher-margin business. Hawkins relies on segment synergy, an extensive distribution network, and strict regulatory compliance, all of which underpin its core strategy. Sourcing of raw materials and maintaining strong supplier relationships are also critical factors for ongoing success, especially given supply chain variability and competitive pressures in its key markets. Quarter in Review: Results and Operational Drivers During Q1 FY2026, Hawkins achieved record revenue, climbing 15.0% year over year (GAAP). The Water Treatment segment led growth, with sales jumping 28% year-over-year to $149.6 million (GAAP). This was largely the result of the WaterSurplus acquisition, which contributed $29 million in new sales and expanded the company's engineering and filtration system offerings. Gross profit from the Water Treatment segment (GAAP) increased by $8.5 million, though gross margin for the Water Treatment segment slipped one percentage point to 29% due to integration and acquisition costs. The Food & Health Sciences segment, focused on ingredients and manufacturing for food and dietary supplement businesses, reported GAAP revenue of $89.2 million, up 5% compared to the same period a year ago. However, gross profit in this area fell 3% (GAAP), as weaker pricing from heightened competition offset higher agriculture-related volumes. Margin percentage squeezed to 22% from 23% (GAAP), reflecting these pricing challenges. Industrial Solutions, primarily supplying chemicals and packaged products to industrial manufacturers, saw modest revenue growth of 2%, rising to $54.5 million (GAAP). Cost increases and competitive pricing continued to pressure profitability in this segment, Operating income for the Industrial Solutions segment declined to $5.7 million from $6.1 million in Q1 FY2025. Company-wide, gross profit (GAAP) reached $72.4 million, up 12%. Selling, general and administrative expenses (SG&A) jumped 24%, mainly from the integration of new Water Treatment operations and associated amortization. Net income (GAAP) edged up to $29.2 million. Adjusted EBITDA, a measure of recurring operating profit that removes one-time charges such as acquisition costs, climbed 13% to $57.6 million. The company financed recent acquisitions by increasing debt to $299.0 million, moving the leverage ratio to 1.6 times adjusted EBITDA from 0.86. The company declared a quarterly dividend of $0.18 per share, continuing a trend of annual dividend growth in recent years. Looking Forward: Outlook and Areas to Watch Management said it expects all three segments to achieve profitable growth in FY2026 and reiterated its commitment to investing in higher-margin business areas. However, the company did not provide numeric revenue or profit guidance for the next quarter or fiscal year. It expects the effective annual tax rate to range from 26% to 27% for FY2026. Going forward, investors may want to pay attention to how integration expenses from the WaterSurplus deal affect margins, as well as ongoing competition in Food & Health Sciences and Industrial Solutions. Balance sheet leverage is up after acquisition activity, so monitoring debt levels and interest expenses will be important. Weather and seasonality, especially for Water Treatment, could also influence segment results and working capital needs in coming quarters. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,049%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of July 29, 2025
